$5.04
6.15%
NYSE, Sep 18, 04:00 pm EDT. Closed.
ISIN
US80880W1062
Symbol
SCLX

Scilex Stock price

$5.04
-1.30 20.50% 1M
+0.23 4.85% 6M
-2.56 33.65% YTD
-10.94 68.45% 1Y
-38.11 88.32% 3Y
-213.32 97.69% 5Y
-211.14 97.67% 10Y
-211.14 97.67% 20Y
NYSE, Closing price Fri, Sep 18 2026
-0.33 6.15%
ISIN
US80880W1062
Symbol
SCLX
Industry

Is Scilex a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
$35.5m
Enterprise Value
$157.0m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
0.8 | 0.6
EV/Sales
3.4 | 2.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-170.7%
Return on Equity
96.6%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $58.0m
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 24.2%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
2.9%
Employees
34
Rev per Employee
$1.4m

Scilex Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Scilex forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Scilex forecast:

Hold
50%
Sell
50%

Financial data from Scilex

Dec '23
+/-
%
47 47
292% 292%
100%
- Direct Costs 16 16
248% 248%
34%
31 31
319% 319%
66%
- Selling and Administrative Expenses 120 120
409% 409%
256%
- Research and Development Expense 13 13
390% 390%
27%
-101 -101
380% 380%
-217%
- Depreciation and Amortization 4.11 4.11
299% 299%
9%
EBIT (Operating Income) EBIT -105 -105
376% 376%
-226%
Net Profit -167 -167
867% 867%
-357%

In millions USD.

Don't miss a Thing! We will send you all news about Scilex directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Scilex Stock News

Neutral
GlobeNewsWire
3 months ago
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies, today announced the signing of a binding term sheet with iHolding Group LLP (“iHolding”), a private investment group headquartered in...
Neutral
GlobeNewsWire
3 months ago
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Dream Bowl I Meme Coin tok...
Neutral
GlobeNewsWire
3 months ago
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet...
More Scilex News

Company Profile

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Head office United States
CEO Dr. Ji
Employees 34
Founded 2020
Website www.scilexholding.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today